GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » 10-Year RORE %

OncoVista Innovative Therapies (OncoVista Innovative Therapies) 10-Year RORE % : 0.00% (As of Sep. 2015)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. OncoVista Innovative Therapies's 10-Year RORE % for the quarter that ended in Sep. 2015 was 0.00%.

The industry rank for OncoVista Innovative Therapies's 10-Year RORE % or its related term are showing as below:

OVIT's 10-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -4.99
* Ranked among companies with meaningful 10-Year RORE % only.

OncoVista Innovative Therapies 10-Year RORE % Historical Data

The historical data trend for OncoVista Innovative Therapies's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies 10-Year RORE % Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoVista Innovative Therapies's 10-Year RORE %

For the Biotechnology subindustry, OncoVista Innovative Therapies's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's 10-Year RORE % falls into.



OncoVista Innovative Therapies 10-Year RORE % Calculation

OncoVista Innovative Therapies's 10-Year RORE % for the quarter that ended in Sep. 2015 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.14--0.012 )/( -2.035-0 )
=-0.128/-2.035
=6.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2015 and 10-year before.


OncoVista Innovative Therapies  (OTCPK:OVIT) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


OncoVista Innovative Therapies 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines